GSA Capital Partners LLP acquired a new position in shares of Bruker Corporation (NASDAQ:BRKR - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 22,553 shares of the medical research company's stock, valued at approximately $941,000.
Other hedge funds have also recently bought and sold shares of the company. Pinnacle Bancorp Inc. purchased a new position in Bruker during the 1st quarter worth $29,000. Allworth Financial LP boosted its holdings in Bruker by 92.4% during the 1st quarter. Allworth Financial LP now owns 758 shares of the medical research company's stock worth $30,000 after acquiring an additional 364 shares during the last quarter. MassMutual Private Wealth & Trust FSB boosted its holdings in Bruker by 274.9% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 1,091 shares of the medical research company's stock worth $46,000 after acquiring an additional 800 shares during the last quarter. Fifth Third Bancorp raised its stake in shares of Bruker by 54.2% during the 1st quarter. Fifth Third Bancorp now owns 1,109 shares of the medical research company's stock worth $46,000 after purchasing an additional 390 shares during the period. Finally, UMB Bank n.a. boosted its holdings in shares of Bruker by 45.8% in the 1st quarter. UMB Bank n.a. now owns 1,325 shares of the medical research company's stock worth $55,000 after buying an additional 416 shares during the last quarter. 79.52% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several analysts have commented on the stock. Wells Fargo & Company lowered their price objective on shares of Bruker from $75.00 to $60.00 and set an "overweight" rating on the stock in a research report on Thursday, April 17th. Bank of America lowered their price objective on shares of Bruker from $61.00 to $50.00 and set a "buy" rating on the stock in a research report on Thursday, June 26th. Barclays lowered their price objective on shares of Bruker from $50.00 to $46.00 and set an "overweight" rating on the stock in a research report on Thursday, May 8th. The Goldman Sachs Group lowered their price objective on shares of Bruker from $50.00 to $45.00 and set a "neutral" rating on the stock in a research report on Thursday, May 8th. Finally, UBS Group lowered their price objective on Bruker from $57.00 to $45.00 and set a "neutral" rating on the stock in a research note on Thursday, May 8th. Six research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Bruker currently has a consensus rating of "Hold" and an average price target of $52.89.
View Our Latest Research Report on BRKR
Bruker Price Performance
Shares of BRKR traded down $0.44 during midday trading on Friday, hitting $37.99. 4,047,076 shares of the company traded hands, compared to its average volume of 3,276,751. The stock has a 50-day moving average of $39.94 and a 200-day moving average of $43.46. Bruker Corporation has a one year low of $34.10 and a one year high of $72.94. The firm has a market cap of $5.76 billion, a P/E ratio of 73.06, a PEG ratio of 2.56 and a beta of 1.16. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.57 and a quick ratio of 0.74.
Bruker (NASDAQ:BRKR - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The medical research company reported $0.47 EPS for the quarter, topping the consensus estimate of $0.46 by $0.01. Bruker had a return on equity of 19.47% and a net margin of 2.31%. The company had revenue of $801.40 million during the quarter, compared to analyst estimates of $763.83 million. During the same quarter in the previous year, the firm earned $0.53 earnings per share. Bruker's revenue was up 11.0% on a year-over-year basis. As a group, sell-side analysts predict that Bruker Corporation will post 2.69 EPS for the current fiscal year.
Bruker Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Stockholders of record on Monday, June 16th were issued a dividend of $0.05 per share. The ex-dividend date of this dividend was Monday, June 16th. This represents a $0.20 annualized dividend and a dividend yield of 0.5%. Bruker's payout ratio is presently 38.46%.
Insider Activity at Bruker
In other Bruker news, CEO Frank H. Laukien acquired 2,608 shares of the business's stock in a transaction dated Friday, June 6th. The stock was bought at an average price of $38.36 per share, with a total value of $100,042.88. Following the completion of the acquisition, the chief executive officer owned 38,462,171 shares of the company's stock, valued at $1,475,408,879.56. This trade represents a 0.01% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 27.30% of the company's stock.
About Bruker
(
Free Report)
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
See Also

Before you consider Bruker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bruker wasn't on the list.
While Bruker currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.